These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22081789)

  • 1. Systematic Chemical Mutagenesis Identifies a Potent Novel Apratoxin A/E Hybrid with Improved in Vivo Antitumor Activity.
    Chen QY; Liu Y; Luesch H
    ACS Med Chem Lett; 2011 Nov; 2(11):861-865. PubMed ID: 22081789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity.
    Chen QY; Liu Y; Cai W; Luesch H
    J Med Chem; 2014 Apr; 57(7):3011-29. PubMed ID: 24660812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm.
    Cai W; Ratnayake R; Wang M; Chen QY; Raisch KP; Dang LH; Law BK; Luesch H
    Curr Res Pharmacol Drug Discov; 2021; 2():100053. PubMed ID: 34909679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.
    Cai W; Chen QY; Dang LH; Luesch H
    ACS Med Chem Lett; 2017 Oct; 8(10):1007-1012. PubMed ID: 29057042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation.
    Liu Y; Law BK; Luesch H
    Mol Pharmacol; 2009 Jul; 76(1):91-104. PubMed ID: 19403701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model.
    Cai W; Ratnayake R; Gerber MH; Chen QY; Yu Y; Derendorf H; Trevino JG; Luesch H
    Invest New Drugs; 2019 Apr; 37(2):364-374. PubMed ID: 30073464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouillonii.
    Tidgewell K; Engene N; Byrum T; Media J; Doi T; Valeriote FA; Gerwick WH
    Chembiochem; 2010 Jul; 11(10):1458-66. PubMed ID: 20512792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apratoxin Kills Cells by Direct Blockade of the Sec61 Protein Translocation Channel.
    Paatero AO; Kellosalo J; Dunyak BM; Almaliti J; Gestwicki JE; Gerwick WH; Taunton J; Paavilainen VO
    Cell Chem Biol; 2016 May; 23(5):561-566. PubMed ID: 27203376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61.
    Huang KC; Chen Z; Jiang Y; Akare S; Kolber-Simonds D; Condon K; Agoulnik S; Tendyke K; Shen Y; Wu KM; Mathieu S; Choi HW; Zhu X; Shimizu H; Kotake Y; Gerwick WH; Uenaka T; Woodall-Jappe M; Nomoto K
    Mol Cancer Ther; 2016 Jun; 15(6):1208-16. PubMed ID: 27196783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformation-Based Design and Synthesis of Apratoxin A Mimetics Modified at the α,β-Unsaturated Thiazoline Moiety.
    Onda Y; Masuda Y; Yoshida M; Doi T
    J Med Chem; 2017 Aug; 60(15):6751-6765. PubMed ID: 28682609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the marine cyanobacteria Lyngbya majuscula and Lyngbya sordida.
    Gutiérrez M; Suyama TL; Engene N; Wingerd JS; Matainaho T; Gerwick WH
    J Nat Prod; 2008 Jun; 71(6):1099-103. PubMed ID: 18444683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts.
    Serrill JD; Wan X; Hau AM; Jang HS; Coleman DJ; Indra AK; Alani AW; McPhail KL; Ishmael JE
    Invest New Drugs; 2016 Feb; 34(1):24-40. PubMed ID: 26563191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation, Structure Elucidation, and Biological Activity of the Selective TACR2 Antagonist Tumonolide and its Aldehyde from a Marine Cyanobacterium.
    Kokkaliari S; Grauso L; Mangoni A; Seabra G; Paul VJ; Luesch H
    Chemistry; 2024 Jul; ():e202401393. PubMed ID: 39023398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O; Laird AD; Nannini MA; Barone A; Li G; Moss KG; Cherrington JM; Mendel DB
    Mol Cancer Ther; 2006 May; 5(5):1280-9. PubMed ID: 16731761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apratoxin S4 Inspired by a Marine Natural Product, a New Treatment Option for Ocular Angiogenic Diseases.
    Qiu B; Tan A; Veluchamy AB; Li Y; Murray H; Cheng W; Liu C; Busoy JM; Chen QY; Sistla S; Hunziker W; Cheung CMG; Wong TY; Hong W; Luesch H; Wang X
    Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):3254-3263. PubMed ID: 31361305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total synthesis of apratoxin A and B using Matteson's homologation approach.
    Andler O; Kazmaier U
    Org Biomol Chem; 2021 Jun; 19(22):4866-4870. PubMed ID: 33998628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent Synthesis of Revised Apratoxin E, 30-epi-Apratoxin E, and 30S/30R-Oxoapratoxin E.
    Mao ZY; Si CM; Liu YW; Dong HQ; Wei BG; Lin GQ
    J Org Chem; 2017 Oct; 82(20):10830-10845. PubMed ID: 28933840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of the biologically active natural product cyclodepsipeptides apratoxin A and its analogues.
    Doi T
    Chem Pharm Bull (Tokyo); 2014; 62(8):735-43. PubMed ID: 25087625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.